ESMO 2023 | How the landscape of treating CRPC has evolved with the introduction of targeted treatment

Rob Jones, MD, PhD, The University of Glasgow, Glasgow, UK, discusses the evolving landscape of treating castration-resistant prostate cancer (CRPC) with the introduction of targeted treatments. In the past five years, the nature of CRPC has shifted, with patients often having already received androgen receptor-targeted therapies (e.g., enzalutamide, abiraterone) in the hormone-sensitive state. Modern-day CRPC encompasses resistance not just to castration but also to androgen receptor-targeted therapies. This presents challenges in therapeutic options, especially as patients may progress rapidly. Prof. Jones explores the limitations of sequential therapies and highlights emerging options, such as PARP inhibitors (e.g., olaparib) and combination trials with androgen receptor therapies. The complexity of these treatments and their efficacy in patients with specific mutations, particularly BRCA or HRD, necessitates further research to optimize CRPC management. This interview took place at the Global Congress on Prostate and Bladder Cancer (PROSCA/BLADDR) 2023 in Malaga, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.